Conference Correspondent

Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, the addition of tucatinib to trastuzumab and capecitabine showed clinically meaningful improvements in efficacy independent of hormone receptor status. Read More ›

ARX788-211 is a phase 2/3 randomized, multicenter, open-label trial comparing ARX788 with lapatinib and capecitabine in patients with HER2-positive, locally advanced, or metastatic breast cancer. Read More ›

Interim safety and efficacy analysis of a phase 1b/2 clinical trial of tucatinib, palbociclib, and letrozole in patients with HR-positive and HER2-positive metastatic breast cancer demonstrates antitumor activity and safety profile that warrant future studies. Read More ›

The use of circulating tumor cells to monitor HER2 status may help to identify patients who could benefit from a modified treatment approach with anti-HER2 therapy, through supplementation or switching to another therapy as necessary based on receptor switch. Read More ›

Geriatric patients with HER2-positive advanced breast cancer demonstrated shorter chemotherapy durations, poorer overall survival, and increased rates of adverse events, highlighting the need for prospective studies to improve outcomes. Read More ›

The healthcare resource utilization of brain metastases is significantly higher among patients with HER2-positive metastatic breast cancer compared with patients without brain metastases, emphasizing the critical need for effective systemic therapies that improve outcomes and decrease the burden of disease. Read More ›

Retreatment with pertuzumab as either third- or fourth-line chemotherapy was both effective and reasonable in patients with HER2-positive locally advanced/metastatic breast cancer and may be considered a standard treatment practice. Read More ›

An increase in neoadjuvant therapy use has paralleled shifts in the standard anti-HER2 therapies; however, neoadjuvant patients are primarily treated with dual HER2 blockade and chemotherapy, with a taxane-based regimen preference. Read More ›

Contemporaneous monitoring of HER2 status with circulating tumor cells may help to identify patients who may benefit from modifying the treatment approach with anti-HER2 therapy, through supplementation or switching to another therapy as necessary based on receptor switch. Read More ›

In the HER2-positive metastatic breast cancer setting, trastuzumab-based therapy can support a full recovery. In patients who have achieved a long-term complete response, discontinuation of therapy may be considered appropriate. Read More ›